Latest Cancer News

SWOG Study Shows Strong Long-Term Survival Rates for Patients with GIST (04-26-2017)

PORTLAND, OR – Nine years ago, SWOG researchers confirmed a new standard of care for patients with incurable gastrointestinal stromal tumors (GIST), who could survive by being treated with imatinib mesylate, the breakthrough drug marketed as Gleevec. SWOG researchers are back with long-term findings from that study, which estimate that nearly one [...]

Revlimid Maintenance Therapy Related to More Secondary Primary Malignancies in Older Adults (04-25-2017)

Results from a pivotal clinical trial have supported the use of Revlimid (lenalidomide) as maintenance therapy for patients multiple myeloma.  A new analysis from the trial just published in the Journal, Blood raises concerns about the safety of Revlimd maintenance reporting an increased risk of developing secondary cancer. Doctors from [...]

Recruitment Begins for World’s First Ovarian Cancer Vaccine Trial (04-25-2017)

UConn Health is beginning to recruit patients for the world’s first personalized genomics-driven ovarian cancer vaccine clinical trial. The goal: to prevent an often deadly relapse of the disease in women diagnosed at advanced stages. The pioneering injectable vaccine OncoImmunome works by boosting the patient’s immune response to enable it [...]

Immune Therapy Produces Anti-Cancer Responses in Advanced Cervical Cancer (04-24-2017)

Adoptive T-cell therapy (ACT) appears to provide anti-cancer responses among patients with advanced cervical cancer for whom standard therapy has stopped working. These results were published in the Journal of Clinical Oncology. The most common cause of cervical cancer is infection with particular strains of the human papillomavirus (HPV). As [...]

Immunotherapy for Glioblastoma Well Tolerated; Survival Gains Observed (04-21-2017)

Small, phase one trial of a dendritic cell vaccine supports further study in larger trials A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival [...]

Combination Immunotherapy with Yervoy and Opdivo Improves Overall Survival Compared to Yervoy Alone in Patients with Previously Untreated Advanced Melanoma (04-19-2017)

The first overall survival data from the CheckMate -067 clinical trial evaluating Yervoy (ipilumamab) and Opdivo (nivolumab) combinations has just been reported.  The two-year survival rates were 64% for the Opdivo plus Yervoy combination, 59% for Opdivo alone and 45% for Yervoy alone. About Opdivo Opdivo is a programmed death-1 (PD-1) [...]

Tagrisso Approved for Treatment of Certain Lung Cancers (04-18-2017)

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. [...]

Breast cancer rates increasing among Asian Americans (04-17-2017)

Researchers examined breast cancer incidence rates among seven Asian American ethnic groups in this new study.  In contrast to other US racial/ethnic groups, Asian Americans have experienced steadily increasing breast cancer rates over the past 15 years. To better understand potential contributors to this increase, researchers at the Cancer Prevention [...]

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer (04-13-2017)

Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data presented here at the AACR Annual Meeting in Washington DC this week. Lung cancer remains the leading cause [...]

Tecentriq Plus Abraxane Results Suggest Novel Immunotherapy PD-1 “Checkpoint” Inhibitors Have Role in Management of Triple-Negative Breast Cancer (04-12-2017)

The investigative agent, Tecentriq (atezolizumb), in addition to the chemotherapy agent, Abraxane (nab-paclitaxel), provides high anti-cancer responses among patients with triple-negative breast cancer. Approximately 10-20% of breast cancers are referred to as triple-negative breast cancer (TNBC). These types of cancers are both hormone-negative and HER2-negative. Hormone-negative breast cancer refers to [...]

Keytruda Shows Promise in Treatment of Mesothelioma (04-4-2017)

Keytruda (pembrolizumab), an antibody drug already used to treat other forms of cancer, can be effective in the treatment of the most common form of mesothelioma, according to a new study led by investigators from the Perelman School of Medicine at the University of Pennsylvania. The study, published in The [...]

Niraparib Approved for Ovarian Cancer Maintenance Treatment (04-3-2017)

Zejula (Niraparib) has been approved by the US Food and Drug Administration (FDA) for use as maintenance therapy in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal who are in complete or partial response to platinum-based chemotherapy. Niraparib is a poly ADP-ribose polymerase (PARP) inhibitor, but unlike other [...]

Next Page »